About 200 reports

  • GLOBAL PREMATURE EJACULATION TREATMENT MARKET BY SSRIS 2016-2021 ($ MILLIONS)
  • SSRIS

About Premature Ejaculation Treatment Premature ejaculation is one of the most common sexual dysfunctions occurring in men. Ejaculation happens sooner than desired, either shortly or before penetration, resulting in distress to either one or both partners involved in sexual intercourse. There is no exact cause that...

  • Pharmaceutical
  • Therapy
  • World
  • Forecast
  • Eli Lilly & Co.
  • NEURODEGENERATIVE DISORDERS THERAPEUTICS MARKET, COMORBIDITIES ASSOCIATED WITH

Global Neurodegenerative Drugs Market to 2022 - Growth Driven by an Aging Population, the Approval of Novel Immunomodulators and Neuromodulators, and Strong Uptake of Marketed Anti-Inflammatory Treatments Summary Neurodegenerative disorders are a cluster of conditions that affect the central nervous system. They include...

  • Clinical Trial
  • Dementia
  • Therapy
  • World
  • Biogen Idec Inc.
  • UNIPOLAR DEPRESSION

About Antipsychotic Drugs Antipsychotic drugs are also called as major tranquilizers or neuroleptics. These drugs are primarily used for the treatment of psychiatric disorders such as schizophrenia, hallucinations, delusions, bipolar disorder, and others. The antipsychotic drugs market is expected to grow due to the rising number...

  • Antipsychotic
  • Psychotic Disorder
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • GlaxoSmithKline plc
  • 4.5 Personality Disorders
  • 20 Personality disorders market, 2014 - 2025 (USD Billion)

The global behavioral rehabilitation market is expected to reach USD 313.9 billion by 2025, according to a new report by Grand View Research, Inc. Behavioral rehabilitation market is anticipated to experience growth during the forecast period due to presence of favorable government initiatives, rising number of service providers, and growing...

  • Healthcare
  • United States
  • Forecast
  • PIPELINE BY TAKEDA PHARMACEUTICAL CO LTD, H2 2017
  • KYOWA HAKKO KIRIN CO LTD

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Therapy
  • World
  • Product Initiative
  • Gilead Sciences, Inc.
  • Products and services segmentation (2017)
  • INDUSTRY DEFINITION

Road to recovery: Demand will increase as mental health becomes less socially stigmatized Abstract Mental Health & Substance Abuse Centres in Canada Over the five years to 2017, the rising awareness and acceptance of mental health and substance abuse illnesses have contributed to steady...

  • Addiction Disorder
  • Mental Health
  • Pathology
  • Canada
  • Demand
  • KYOWA HAKKO KIRIN ENTERS INTO LICENSING AGREEMENT WITH SANDOZ

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Biosimilar
  • Healthcare
  • Monoclonal Antibody
  • Pharmaceutical
  • Sandoz Inc.
  • Kyowa Hakko Kirin Co Ltd (4151)
  • ASSET TRANSACTIONS

It targets Histone Deacetylase ##.

  • Asthma
  • Healthcare
  • Pharmaceutical
  • Therapy
  • Kyowa Hakko Kirin Co., Ltd.
  • Description

Chapter ## provides an introduction to the report.

  • Mental Health
  • Pathology
  • World
  • Demand
  • PIPELINE BY TAKEDA PHARMACEUTICAL CO LTD, H1 2018
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Digestive System Disorder
  • Hormone
  • Therapy
  • World
  • Gilead Sciences, Inc.
  • LEO PHARMA AND LEO PHARMA A/S ENTER INTO AGREEMENT WITH KYOWA HAKKO KIRIN
  • LEO PHARMA ENTERS INTO DISTRIBUTION AND CO-PROMOTION AGREEMENT WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Dermatological Condition
  • Healthcare
  • Pathology
  • Pharmaceutical
  • LEO Pharma A/S
  • PIPELINE BY HORIZON DISCOVERY GROUP PLC, H2 2017
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H2 2017

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Hospital
  • Oncology
  • Research And Development
  • Therapy
  • AstraZeneca PLC
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018
  • PIPELINE BY COTINGA PHARMACEUTICALS INC, H1 2018

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Hospital
  • Oncology
  • Therapy
  • World
  • AstraZeneca PLC
  • PIPELINE BY KYOWA HAKKO KIRIN CO., LTD., H1 2016
  • FLX Bio Inc

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H1 2018 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation....

  • Chemokine
  • Therapy
  • United States
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • GLOBAVIR BIOSCIENCES INC
  • PIPELINE BY GLOBAVIR BIOSCIENCES INC, H2 2017

C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor...

  • Chemokine
  • Lymphoma
  • Therapy
  • World
  • Kyowa Hakko Kirin Co., Ltd.
  • 7.2 EUROPE

According to a report by European Neuropharmacology, about ##, ##, ## French citizens are suffering from neurological disorders, among which, ##, ##, ## people are in the ##-## age bracket, including seven new brain disorders, such as child disorders, eating disorders, men

  • Medical Device
  • Neurological Monitoring
  • Patient Monitoring
  • United States
  • Market Size
  • KYOWA HAKKO KIRIN CO LTD
  • JOHNSON & JOHNSON

Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Pipeline Review, H2 2018 Summary Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5...

  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • Apexigen, Inc.
  • ACTIVIOMICS ENTERS INTO RESEARCH AGREEMENT WITH KYOWA HAKKO
  • ACTIVIOMICS EXTENDS RESEARCH AGREEMENT WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Influenza
  • Pharmaceutical
  • United Kingdom
  • hVIVO plc
  • LICENSING AGREEMENTS

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Biotech
  • Biotechnology
  • Healthcare
  • Pharmaceutical
  • SBI Biotech Co., Ltd
  • PIPELINE BY JOHNSON & JOHNSON, H1 2018
  • KYOWA HAKKO KIRIN CO LTD

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Monoclonal Antibody
  • Therapy
  • United States
  • World
  • Product Initiative
  • ASSET PURCHASE

ITS DEVELOPMENT PIPELINE CONSISTS OF VARIOUS PROTEIN, ANTIBODY AND SMALL MOLECULE FORMULATIONS FOR THE TREATMENT OF NEUTROPENIA, ANEMIA, CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA, HYPERTENSION, ANGINA PECTORIS, ALLERGIC RHINITIS, EPILEPSY, BEHAVIORAL OR PERSONALITY DISORDERS AND

  • Healthcare
  • Pharmaceutical
  • Therapy
  • Australia
  • Aspen Pharmacare Holdings Limited
  • Clinical Trial profile. 500 Trial Title
  • 5. All the trials included are unique trials.

Cognitive Disorders Global Clinical Trials Review, H1, 2017 Summary GlobalData’s clinical trial report, “Cognitive Disorders Global Clinical Trials Review, H1, 2017" provides an overview of Cognitive Disorders clinical trials scenario. This report provides top line data relating to the clinical trials on Cognitive Disorders....

  • Clinical Trial
  • Dementia
  • Hospital
  • Neurology
  • Pharmaceutical
  • Description

The mental health centers market comprises of establishments providing healthcare and rehabilitation services to the mentally different and intellectually challenged. Mental illnesses can vary from anxiety and bipolar disorder to paranoia and personality disorder. The market is further classified into residential and outpatient centers. The...

  • Mental Health
  • Pathology
  • World
  • 2.3 GLOBAL TRENDS

Service system: epidermiologic catchment area prospective ##-year prevalence rates of the disorders and services.

  • Mental Health
  • Pathology
  • Psychotic Disorder
  • Japan
  • Forecast
  • KYOWA HAKKO KIRIN CO LTD
  • PIPELINE BY KYOWA HAKKO KIRIN CO LTD, H1 2018

Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) - Pipeline Review, H1 2018 Summary Transient Receptor Potential Cation Channel Subfamily V Member 1 (Capsaicin Receptor or Vanilloid Receptor 1 or TRPV1) pipeline Target constitutes...

  • Pain Relief
  • Pharmaceutical
  • Research And Development
  • Therapy
  • Flex Pharma, Inc.
  • SANFORD HEALTH ACQUIRES HEMATECH, DRUG DEVELOPMENT COMPANY
  • SANFORD HEALTH ACQUIRES HEMATECH, DRUG DEVELOPMENT COMPANY

Medcenter One Inc Medcenter One, Inc.

  • Health Services
  • Healthcare
  • Pharmaceutical
  • United States
  • Caladrius Biosciences, Inc.
  • R&D EXPENSE
  • Kyowa Hakko Kirin - Overview

The Mid-Size Pharmaceutical Market: Market Assessment, Growth Forecasts and Strategic Consolidations for Key Players Summary The worldwide pharmaceutical market is projected to grow from approximately $1.1 trillion in 2016 to $1.5 trillion in 2021, representing a compound annual growth rate of 6.4%....

  • Pharmaceutical
  • Therapy
  • Alexion Pharmaceuticals, Inc.
  • Daiichi Sankyo Company
  • Eisai Co., Ltd.
  • FUJIFILM FORMS JOINT VENTURE WITH KYOWA HAKKO KIRIN

Its development pipeline consists of various protein, antibody and small molecule formulations for the treatment of neutropenia, anemia, chronic idiopathic thrombocytopenic purpura, hypertension, angina pectoris, allergic rhinitis, epilepsy, behavioral or personality disorders and

  • Healthcare
  • Pharmaceutical
  • Therapy
  • United States
  • FUJIFILM Holdings Corporation
  • CLINICAL TRIAL PROFILE SNAPSHOTS

THE PROMINENT FEATURES OF THIS REPORT ARE - ##.

  • Clinical Trial
  • Drug Discovery And Development
  • Hospital
  • Neurology
  • Therapy
  • COMPANY OVERVIEW
  • Key Executives

Kyowa Hakko Kirin Co Ltd (4151) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and...

  • Pharmaceutical
  • Japan
  • Company Financials
  • Kyowa Hakko Kirin Co., Ltd.